KRT88P and cancer: According to the American Association for the Study of Liver Diseases (AASLD), HBVr from anti-cancer therapies occurred in 41% to 53% of HBsAg−positive and anti-HBc–positive patients, and 8% to 18% of HBsAg−negative, anti-HBc–positive patients [9].